Increased serum levels of sortilin-derived propeptide after electroconvulsive therapy in treatment-resistant depressed patients

Morgane Roulot,1,&dagger; Alessandra Minelli,2 Marco Bortolomasi,3 Elisabetta Maffioletti,2,4 Massimo Gennarelli,2,4 Marc Borsotto,1 Catherine Heurteaux,1 Jean Mazella1 1Molecular and Cellular Institute of Pharmacology, CNRS, Institut de Pharmacologie Moléculaire et Cellulaire, UMR 7...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Roulot M, Minelli A, Bortolomasi M, Maffioletti E, Gennarelli M, Borsotto M, Heurteaux C, Mazella J
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	sortilin propeptide electroconvulsive therapy treatment resistant depressed patients diagnosis Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/9a2e4ce36679435ea3e688402f8dc94f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9a2e4ce36679435ea3e688402f8dc94f
record_format	dspace
spelling	oai:doaj.org-article:9a2e4ce36679435ea3e688402f8dc94f2021-12-02T08:28:38ZIncreased serum levels of sortilin-derived propeptide after electroconvulsive therapy in treatment-resistant depressed patients1178-2021https://doaj.org/article/9a2e4ce36679435ea3e688402f8dc94f2018-09-01T00:00:00Zhttps://www.dovepress.com/increased-serum-levels-of-sortilin-derived-propeptide-after-electrocon-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Morgane Roulot,1,&dagger; Alessandra Minelli,2 Marco Bortolomasi,3 Elisabetta Maffioletti,2,4 Massimo Gennarelli,2,4 Marc Borsotto,1 Catherine Heurteaux,1 Jean Mazella1 1Molecular and Cellular Institute of Pharmacology, CNRS, Institut de Pharmacologie Moléculaire et Cellulaire, UMR 7275, Université Côte d’Azur, Valbonne, France; 2Department of Molecular and Translational Medicine, Biology and Genetic Division, University of Brescia, Brescia, Italy; 3Psychiatric Hospital “Villa Santa Chiara”, Verona, Italy; 4Genetic Unit, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy &dagger;Morgane Roulot passed away on January 10, 2018 Purpose: Sortilin-derived propeptide (PE) and its synthetic analog spadin show strong antidepressant activity in rodents and, therefore, could be used as a biomarker to evaluate the clinical efficacy of antidepressant treatments. The aim of this study was to determine whether electroconvulsive therapy (ECT) modulates serum PE concentration in patients with treatment-resistant depression (TRD).Patients and methods: Forty-five patients with major depressive disorder, who met the Diagnostic and Statistical Manual of Mental Disorders-IV criteria, were selected for this study.Results: We did not observe any difference in the PE levels between TRD patients and controls (z=0.10, P=0.92), but we found a strong significant increase between the PE levels measured just before (T0) and about 1 month (T2) after ECT (z=-2.82, P=0.005). A significant difference between T0 and T2 was observed only in responders (z=-2.59, P=0.01), whereas no effect was found in nonresponders (z=-1.27, P=0.20). Interestingly, we found a significant correlation between the increase in PE levels and decrease in Montgomery -Åsberg Depression Rating Scale scores for the total patient sample (P=0.03).Conclusion: This study indicates for the first time that ECT affects serum PE concentration in responders and, therefore, could contribute to the evaluation of the therapy success. Keywords: sortilin propeptide, electroconvulsive therapy, treatment-resistant depressed patients, diagnosisRoulot MMinelli ABortolomasi MMaffioletti EGennarelli MBorsotto MHeurteaux CMazella JDove Medical Pressarticlesortilin propeptideelectroconvulsive therapytreatment resistant depressed patientsdiagnosisNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 14, Pp 2307-2312 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	sortilin propeptide electroconvulsive therapy treatment resistant depressed patients diagnosis Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	sortilin propeptide electroconvulsive therapy treatment resistant depressed patients diagnosis Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Roulot M Minelli A Bortolomasi M Maffioletti E Gennarelli M Borsotto M Heurteaux C Mazella J Increased serum levels of sortilin-derived propeptide after electroconvulsive therapy in treatment-resistant depressed patients
description	Morgane Roulot,1,&dagger; Alessandra Minelli,2 Marco Bortolomasi,3 Elisabetta Maffioletti,2,4 Massimo Gennarelli,2,4 Marc Borsotto,1 Catherine Heurteaux,1 Jean Mazella1 1Molecular and Cellular Institute of Pharmacology, CNRS, Institut de Pharmacologie Moléculaire et Cellulaire, UMR 7275, Université Côte d’Azur, Valbonne, France; 2Department of Molecular and Translational Medicine, Biology and Genetic Division, University of Brescia, Brescia, Italy; 3Psychiatric Hospital “Villa Santa Chiara”, Verona, Italy; 4Genetic Unit, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy &dagger;Morgane Roulot passed away on January 10, 2018 Purpose: Sortilin-derived propeptide (PE) and its synthetic analog spadin show strong antidepressant activity in rodents and, therefore, could be used as a biomarker to evaluate the clinical efficacy of antidepressant treatments. The aim of this study was to determine whether electroconvulsive therapy (ECT) modulates serum PE concentration in patients with treatment-resistant depression (TRD).Patients and methods: Forty-five patients with major depressive disorder, who met the Diagnostic and Statistical Manual of Mental Disorders-IV criteria, were selected for this study.Results: We did not observe any difference in the PE levels between TRD patients and controls (z=0.10, P=0.92), but we found a strong significant increase between the PE levels measured just before (T0) and about 1 month (T2) after ECT (z=-2.82, P=0.005). A significant difference between T0 and T2 was observed only in responders (z=-2.59, P=0.01), whereas no effect was found in nonresponders (z=-1.27, P=0.20). Interestingly, we found a significant correlation between the increase in PE levels and decrease in Montgomery -Åsberg Depression Rating Scale scores for the total patient sample (P=0.03).Conclusion: This study indicates for the first time that ECT affects serum PE concentration in responders and, therefore, could contribute to the evaluation of the therapy success. Keywords: sortilin propeptide, electroconvulsive therapy, treatment-resistant depressed patients, diagnosis
format	article
author	Roulot M Minelli A Bortolomasi M Maffioletti E Gennarelli M Borsotto M Heurteaux C Mazella J
author_facet	Roulot M Minelli A Bortolomasi M Maffioletti E Gennarelli M Borsotto M Heurteaux C Mazella J
author_sort	Roulot M
title	Increased serum levels of sortilin-derived propeptide after electroconvulsive therapy in treatment-resistant depressed patients
title_short	Increased serum levels of sortilin-derived propeptide after electroconvulsive therapy in treatment-resistant depressed patients
title_full	Increased serum levels of sortilin-derived propeptide after electroconvulsive therapy in treatment-resistant depressed patients
title_fullStr	Increased serum levels of sortilin-derived propeptide after electroconvulsive therapy in treatment-resistant depressed patients
title_full_unstemmed	Increased serum levels of sortilin-derived propeptide after electroconvulsive therapy in treatment-resistant depressed patients
title_sort	increased serum levels of sortilin-derived propeptide after electroconvulsive therapy in treatment-resistant depressed patients
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/9a2e4ce36679435ea3e688402f8dc94f
work_keys_str_mv	AT roulotm increasedserumlevelsofsortilinderivedpropeptideafterelectroconvulsivetherapyintreatmentresistantdepressedpatients AT minellia increasedserumlevelsofsortilinderivedpropeptideafterelectroconvulsivetherapyintreatmentresistantdepressedpatients AT bortolomasim increasedserumlevelsofsortilinderivedpropeptideafterelectroconvulsivetherapyintreatmentresistantdepressedpatients AT maffiolettie increasedserumlevelsofsortilinderivedpropeptideafterelectroconvulsivetherapyintreatmentresistantdepressedpatients AT gennarellim increasedserumlevelsofsortilinderivedpropeptideafterelectroconvulsivetherapyintreatmentresistantdepressedpatients AT borsottom increasedserumlevelsofsortilinderivedpropeptideafterelectroconvulsivetherapyintreatmentresistantdepressedpatients AT heurteauxc increasedserumlevelsofsortilinderivedpropeptideafterelectroconvulsivetherapyintreatmentresistantdepressedpatients AT mazellaj increasedserumlevelsofsortilinderivedpropeptideafterelectroconvulsivetherapyintreatmentresistantdepressedpatients
_version_	1718398501674549248

Increased serum levels of sortilin-derived propeptide after electroconvulsive therapy in treatment-resistant depressed patients

Ejemplares similares